Unexpected finding points to potential way to stop macular degeneration
In a major step forward in the battle against macular degeneration, the leading cause of vision loss among the elderly, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the damaging inflammation that ultimately robs millions of their sight. The finding may allow doctors to halt the inflammation early on, potentially saving patients from blindness.
“Almost 200 million people in the world have macular degeneration. If macular degeneration were a country, it would be the eighth most populated nation in the world. That’s how large a problem this is,” said Jayakrishna Ambati, MD, vice chairman for research of UVA’s Department of Ophthalmology and the founding director of UVA’s Center for Advanced Vision Science. “For the first time, we know in macular degeneration what is one of the very first events that triggers the system to get alarmed and start, to use an anthropomorphic term, hyperventilating. This overdrive of inflammation is what ultimately damages cells, and so, potentially, we have a way of interfering very early in the process.”
Potential New Treatment for Macular Degeneration
Ambati and Nagaraj Kerur, PhD, assistant professor in the Department of Ophthalmology, and their laboratories have determined that the culprit is an enzyme called cGAS. The enzyme plays an important role in the body’s immune response to infections by detecting foreign DNA. But the molecule’s newly identified role in the “dry” form of age-related macular degeneration comes as wholly unexpected.
“It’s really surprising that in macular degeneration, which, as far as we know, has nothing to do with viruses or bacteria, that cGAS is activated, and that this alarm system is turned on,” Ambati said. “This is what leads to the killing of the cells in the retina, and, ultimately, vision loss.”
The researchers noted that cGAS may be an alarm not just for pathogens but for other harmful problems that warrant responses from the immune system. The enzyme may also play important roles in conditions such as diabetes, lupus and obesity, and researchers already are working to create drugs that could inhibit its function. “Because the target we’re talking about is an enzyme, we could develop small molecules that could block it,” Kerur said. “There are many drugs already on the market that target specific enzymes, such as the statins [which are used to lower cholesterol levels.]”
The promising new lead comes as good news for researchers seeking to develop new treatments for dry macular degeneration, as clinical trials in recent years have come to dead end after dead end.
The UVA researchers expect the development of a drug to inhibit cGAS will take several years, and that drug would then need to go through extensive testing to determine its safety and effectiveness for combating macular degeneration.
The researchers also hope to develop a way to detect the levels of the enzyme in patients’ eyes. That would let them determine when best to administer a treatment that blocks cGAS. “If they have high levels of this enzyme in their eye, they might be a wonderful candidate for this sort of treatment,” Ambati said. “This is really precision medicine at the single-molecule level.”
The Latest on: Macular degeneration
- UNITY Biotechnology Completes Enrollment in Phase 2 ENVISION Study of UBX1325 in Wet Age-related Macular Degenerationon September 19, 2022 at 5:00 am
Enrollment of 51 patients exceeds target by ~10% due to high interest in the study 16-week data anticipated in Q1 2023 and 24-week data anticipated in Q2 2023 SOUTH SAN FRANCISCO, Calif., Sept. 19, ...
- Roche's Vabysmo Gets EU Approval To Treat Two Major Causes Of Vision Losson September 18, 2022 at 10:15 pm
Swiss drug major Roche (RHHBY) announced Monday that the European Commission approved Vabysmo (faricimab) to treat neovascular or 'wet' age-related macular degeneration or nAMD and visual impairment ...
- Implanting a Patient’s Own Reprogrammed Stem Cells Shows Early Positive Results for Treating Dry AMDon September 15, 2022 at 9:00 pm
Researchers pursue experimental treatments for dry age-related macular degeneration that replace or replenish dead cells in the retina at the back of the eye.
- Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degenerationon September 14, 2022 at 11:55 am
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the ...
- Macular Degeneration Treatment Global Market to Reach $10.65 Billion by 2026 at a CAGR of 7.15%on September 14, 2022 at 2:30 am
The "Macular Degeneration Treatment Market Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
- Aberdeenshire sight loss open days to raise awareness about macular degenerationon September 13, 2022 at 8:30 am
A CHARITY is hosting events across Aberdeenshire to raise awareness about the most common cause of eyesight loss.
- Exploring the limits of mouse models for investigating age-related macular degenerationon September 12, 2022 at 11:57 am
In research on the eye disease AMD, the experimental animals used are often young male mice. This is not optimal for the development of new treatments, as the disease most often affects the ...
- Dr. Yang Ahn of the Ahn Clinic treats macular degeneration and glaucomaon September 12, 2022 at 9:03 am
((SL Advertiser)) Medical acupuncture treats macular degeneration and glaucoma. To book an appointment at the Ahn Clinic call (480) 515-2000 or visit ...
- Macular Degeneration Treatment Global Market Report 2022: Increasing Burden of Retinal Disorders to Bolster Sector Growth - ResearchAndMarkets.comon September 9, 2022 at 5:32 am
The global macular degeneration treatment market is expected to grow from $7.55 billion in 2021 to $8.08 billion in 2022 at a compound annual growth rate (CAGR) of 7.04%. The market is expected to ...
- Study helps reveal the molecular secrets of macular degenerationon September 7, 2022 at 9:07 am
Research led by Sanford Burnham Prebys professor Francesca Marassi, Ph.D., is helping to reveal the molecular secrets of macular degeneration, which causes almost 90% of all age-related vision loss.
via Google News and Bing News